Scarica l'app Stockscreener
2.36
7.76%
0.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.19
Aprire:
$2.29
Volume 24 ore:
24.73M
Relative Volume:
2.42
Capitalizzazione di mercato:
$2.32B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-2.433
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
+3.06%
1M Prestazione:
+14.56%
6M Prestazione:
-26.02%
1 anno Prestazione:
-22.37%
Intervallo 1D:
$2.25
$2.50
Intervallo di 1 settimana:
$2.17
$2.50
Portata 52W:
$1.83
$4.27
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.36 | 2.16B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion - Yahoo Finance
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
Jefferies Maintains ImmunityBio (IBRX) Buy Recommendation - Nasdaq
ImmunityBio Gains Momentum: Bladder Cancer Care Focus - StocksToTrade
Jefferies raises Immunitybio stock price target to $9 on European regulatory progress - Investing.com
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy - Benzinga
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
Immunitybio stock rises after positive EMA recommendation for bladder cancer therapy - Investing.com Canada
ImmunityBio, Moderna among winners of EU drug recommendations this week - Seeking Alpha
Is ImmunityBio Inc a good long term investmentSector Rotation Strategies & Achieve Consistent Profits - earlytimes.in
ImmunityBio Says European Medicines Agency Recommends Conditional Marketing Authorization for Anktiva with BCG for Non-Muscle Invasive Bladder Cancer - marketscreener.com
ImmunityBio Receives EMA Recommendation for ANKTIVA in Europe - TradingView
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - Business Wire
Armistice Capital LLC Acquires New Position in ImmunityBio, Inc. $IBRX - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
Does Anktiva-Driven Revenue Momentum Reshape the Bull Case For ImmunityBio (IBRX)? - Sahm
ImmunityBio, Inc. (IBRX): A Bull Case Theory - Finviz
ImmunityBio, Inc. (IBRX): A bull case theory - MSN
Can ImmunityBio Stock Hold Up When Markets Turn? - Trefis
Is ImmunityBio Inc. stock a smart buy before Fed meeting2025 Price Targets & Safe Entry Zone Tips - Newser
Will ImmunityBio Inc. (26CA) stock benefit from mergersJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Drop Watch & Intraday High Probability Alerts - Newser
Piper Sandler Remains a Buy on ImmunityBio (IBRX) - The Globe and Mail
ImmunityBio Earnings Notes - Trefis
Is ImmunityBio Inc. (26CA) stock undervalued at current priceWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
ImmunityBio (NASDAQ:IBRX) Trading Down 5.4%Should You Sell? - MarketBeat
Lawmakers Invited to FDA Meeting for Soon-Shiong’s Drug - Bloomberg.com
ImmunityBio (IBRX) Slashes 9% on Lack of Leads - Finviz
Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug - Bloomberg.com
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - MSN
ImmunityBio (IBRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
ImmunityBio (NASDAQ:IBRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ImmunityBio Stock Rises Despite Financial Challenges - timothysykes.com
Can ImmunityBio Inc. (26CA) stock sustain free cash flowRisk Management & Reliable Volume Spike Trade Alerts - Newser
Geode Capital Management LLC Acquires 1,487,849 Shares of ImmunityBio, Inc. $IBRX - MarketBeat
Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility - Yahoo Finance
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally - Yahoo Finance
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences - Insider Monkey
ImmunityBio Skyrockets on Positive Trial Results and Sales Growth - StocksToTrade
ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances - timothysykes.com
ImmunityBio’s Immunotherapy Focus Boosts Market Expectations - StocksToTrade
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances - timothysykes.com
ImmunityBio Stock Boosted by Rising Demand for ANKTIVA and Positive Clinical Trials - StocksToTrade
ImmunityBio’s Strong Market Position Boosted by Recent Innovations - timothysykes.com
HEIGHTS CAPITAL MANAGEMENT, INC's ImmunityBio Inc(IBRX) Holding History - GuruFocus
ImmunityBio’s Clinical Advances and Sales Boost Highlight Market Optimism - StocksToTrade
ImmunityBio Stock (IBRX) Opinions on Q3 Revenue Growth - Quiver Quantitative
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):